enGene Therapeutics Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
enGene Therapeutics Inc. (ENGN) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $136.10 million as of 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2026-09-08
- 2026-07-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $136.10M.
- 2026-04-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $182.90M.
- 2026-01-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $30.00M.
- 2025-10-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $55.90M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss |
|---|---|
| 2026-07-31 | $136.10M 10-Q · filed 2026-09-08 |
| 2026-04-30 | $182.90M 10-Q · filed 2026-06-15 |
| 2026-01-31 | $30.00M 10-Q · filed 2026-03-09 |
| 2025-10-31 | $55.90M 10-Q · filed 2026-09-08 |
| 2025-07-31 | $140.60M 10-Q · filed 2025-09-11 |
| 2025-04-30 | $91.80M 10-Q · filed 2025-06-12 |
| 2025-01-31 | $106.30M 10-Q · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |